Notably, abnormalities in the PI3K–Akt–mTOR pathway also play a critical role in the development of breast cancer drug resistance, suggesting that this pathway is a highly promising candidate in breast cancer therapy. This evidence concerns the gene AKT1 and breast carcinoma.